Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis

Peer Review reports

Original Submission
25 Feb 2013	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
7 Mar 2013	Reviewed	Reviewer Report - Mark Rodgers
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
7 Mar 2013	Editorially accepted
28 Jun 2013	Article published	10.1186/2046-4053-2-47

Back to article page